Core Viewpoint - Zhifei Biological's subsidiary has received approval for clinical trials of a combined vaccine, which is expected to enhance vaccination compliance and reduce the number of doses required [1] Group 1: Company Developments - Zhifei Biological announced that its subsidiary, Zhifei Lvzhu, has obtained the clinical trial approval for an acellular combined vaccine targeting whooping cough, diphtheria, tetanus, and type B Haemophilus influenzae [1] - The approval from the National Medical Products Administration is a significant step in the company's product development strategy [1] - The clinical trial is not expected to have a major impact on the company's recent performance, but successful product development could enhance the company's product portfolio and profitability [1]